Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in adult eosinophilic esophagitis
NCT04682639Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of etrasimod in eosinophilic esophagitis (EoE) (3 arms), sponsored by Pfizer. Primary endpoint: Percent Change From Baseline in Esophageal Peak Eosinophil Count at Week 16. Started Dec 2020; status: completed.
02
Drugs
etrasimod
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT04682639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04682639.